NO319144B1 - Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren. - Google Patents

Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren. Download PDF

Info

Publication number
NO319144B1
NO319144B1 NO19960965A NO960965A NO319144B1 NO 319144 B1 NO319144 B1 NO 319144B1 NO 19960965 A NO19960965 A NO 19960965A NO 960965 A NO960965 A NO 960965A NO 319144 B1 NO319144 B1 NO 319144B1
Authority
NO
Norway
Prior art keywords
grb3
vector
sequence
grb2
protein
Prior art date
Application number
NO19960965A
Other languages
English (en)
Norwegian (no)
Other versions
NO960965L (no
NO960965D0 (no
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO960965L publication Critical patent/NO960965L/no
Publication of NO960965D0 publication Critical patent/NO960965D0/no
Publication of NO319144B1 publication Critical patent/NO319144B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO19960965A 1993-09-15 1996-03-08 Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren. NO319144B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9310971A FR2710074B1 (fr) 1993-09-15 1993-09-15 Gène GRB3-3, ses variants et leurs utilisations.
PCT/FR1994/000542 WO1995007981A1 (fr) 1993-09-15 1994-05-09 Gene grb3-3, ses variants et leurs utilisations

Publications (3)

Publication Number Publication Date
NO960965L NO960965L (no) 1996-03-08
NO960965D0 NO960965D0 (no) 1996-03-08
NO319144B1 true NO319144B1 (no) 2005-06-27

Family

ID=9450882

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960965A NO319144B1 (no) 1993-09-15 1996-03-08 Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren.

Country Status (27)

Country Link
US (2) USRE37952E1 (de)
EP (1) EP0719328B1 (de)
JP (1) JP3794697B2 (de)
KR (1) KR100330477B1 (de)
CN (1) CN1098930C (de)
AT (1) ATE196926T1 (de)
AU (1) AU698819B2 (de)
BR (1) BR9407693A (de)
CA (1) CA2169938A1 (de)
CZ (1) CZ288882B6 (de)
DE (1) DE69426121T2 (de)
DK (1) DK0719328T3 (de)
ES (1) ES2152313T3 (de)
FI (1) FI120499B (de)
FR (1) FR2710074B1 (de)
GR (1) GR3034600T3 (de)
HU (1) HU221516B (de)
IL (2) IL110942A (de)
NO (1) NO319144B1 (de)
NZ (1) NZ266162A (de)
PL (1) PL178402B1 (de)
PT (1) PT719328E (de)
RU (1) RU2159815C2 (de)
SK (1) SK281123B6 (de)
UA (1) UA46715C2 (de)
WO (1) WO1995007981A1 (de)
ZA (1) ZA947059B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US6423824B1 (en) 1995-06-07 2002-07-23 Biogen, Inc. CAIP-like gene family
US6171800B1 (en) 1995-06-07 2001-01-09 Biogen, Inc. Method of making and binding CAIP polypeptides
US5837844A (en) * 1995-06-07 1998-11-17 Biogen, Inc. CAIP-like gene family
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997049808A1 (en) * 1996-06-27 1997-12-31 Biogen, Inc. The caip-like gene family
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0998945A1 (de) * 1998-09-30 2000-05-10 Transgene S.A. Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230433D1 (de) * 1991-01-18 2000-01-20 Univ New York Cdns-klonierungsverfahren für rezeptortyrosinkinasezielprotein und hgrb-proteine
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof

Also Published As

Publication number Publication date
FR2710074B1 (fr) 1995-12-08
NZ266162A (en) 1997-11-24
SK281123B6 (sk) 2000-12-11
CA2169938A1 (fr) 1995-03-23
WO1995007981A1 (fr) 1995-03-23
DK0719328T3 (da) 2000-11-13
HUT74273A (en) 1996-11-28
JP3794697B2 (ja) 2006-07-05
USRE37952E1 (en) 2002-12-31
FI961202L (fi) 1996-03-14
NO960965L (no) 1996-03-08
ZA947059B (en) 1995-05-18
IL126756A (en) 2006-06-11
CZ75896A3 (en) 1996-06-12
HU9600668D0 (en) 1996-05-28
CN1098930C (zh) 2003-01-15
CN1133064A (zh) 1996-10-09
NO960965D0 (no) 1996-03-08
IL110942A0 (en) 1994-11-28
DE69426121T2 (de) 2001-05-31
US5831048A (en) 1998-11-03
FR2710074A1 (fr) 1995-03-24
SK34596A3 (en) 1996-07-03
PL178402B1 (pl) 2000-04-28
GR3034600T3 (en) 2001-01-31
PT719328E (pt) 2001-02-28
FI120499B (fi) 2009-11-13
IL110942A (en) 2001-12-23
EP0719328B1 (de) 2000-10-11
ATE196926T1 (de) 2000-10-15
KR100330477B1 (ko) 2002-12-02
BR9407693A (pt) 1997-02-04
EP0719328A1 (de) 1996-07-03
CZ288882B6 (cs) 2001-09-12
AU698819B2 (en) 1998-11-05
DE69426121D1 (de) 2000-11-16
JPH09502357A (ja) 1997-03-11
RU2159815C2 (ru) 2000-11-27
FI961202A0 (fi) 1996-03-14
PL313445A1 (en) 1996-07-08
ES2152313T3 (es) 2001-02-01
UA46715C2 (uk) 2002-06-17
AU6724794A (en) 1995-04-03
HU221516B (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
NO319144B1 (no) Nukleotidsekvens og dens anvendelse, vektor omfattende sekvensen samt farmasoytisk preparat omfattende vektoren.
CA2197890A1 (en) Retinoblastoma protein-interacting zinc finger proteins
Champagne et al. Activation of adenovirus type 2 early region 4 ORF4 cytoplasmic death function by direct binding to Src kinase domain
WO2002019965A2 (en) Heat shock response and virus replication
EP3016972A2 (de) Pro-apoptotische ras- und raf-peptide
CN117756909A (zh) 改进的抗衰老化合物及其在癌症治疗中的用途
KR102566745B1 (ko) 암의 예방 또는 치료를 위한 Runx3 변이 단백질
US6323335B1 (en) Retinoblastoma protein-interacting zinc finger proteins
US20240294587A1 (en) K-ras inhibitor
WO2016156538A1 (en) Peptides that inhibit binding between set and caspase-9
NO321455B1 (no) Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser.
AU722973B2 (en) Grb3-3 gene, variants and uses thereof
US20030083482A1 (en) Compositions and methods for p53-mediated repression of gene expression
US8404806B2 (en) Isolated BRCA1 peptides and method of use
Xu et al. Molecular cloning and characterization of FX3, a novel zinc-finger protein.
US20030105008A1 (en) Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses
US20060160732A1 (en) Compositions and methods for inhibiting cell senescence and hyperproliferative disorders
KR20250021203A (ko) Kras 단백질 안정성 조절 기반 항암 치료기술

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees